Abstract: The invention concerns nucleotide sequences coding for a polypeptide involved in Streptogramin biosynthesis, recombinant cells containing said sequences, and use thereof.
Type:
Grant
Filed:
May 10, 1995
Date of Patent:
April 6, 1999
Assignee:
Rhone-Poulenc Rorer S.A.
Inventors:
Veronique Blanc, Francis Blanche, Joel Crouzet, Nathalie Jacques, Patricia Lacroix, Denis Thibaut, Monique Zagorec, Laurent Debussche, Valerie De Crecy-Lagard
Abstract: Novel modified or derivatized recombinant animal somatotropins. Methods for stabilizing recombinant animal somatotropins by modification or deletion of the Cysteine residues utilizing site directed mutagenesis to replace from one to four of the cysteine amino acid residues of said somatotropins with one or more different amino acid residues or by derivatization of (1) both cysteine amino acid residues in the small loop of said somatotropin, both cysteine amino acid residues in the large loop or the four cysteine amino acid residues in both loops of said somatotropin.
Type:
Grant
Filed:
May 9, 1995
Date of Patent:
April 6, 1999
Assignee:
American Cyanamid Company
Inventors:
Susan Mancini Cady, John Steele Logan, Brian Lee Buckwalter, Gerald William Stockton, Deborah Tardy Chaleff
Abstract: New microorganisms with plasmids stable relative to betaine utilization. These new microorganisms contain (a) a hybrid plasmid with a DNA fragment that contains a genetic sequence that codes for betaine utilization and (b) a mutation in the chromosomal gene coding for the betaine utilization.
Type:
Grant
Filed:
July 21, 1997
Date of Patent:
April 6, 1999
Assignee:
Lonza Ltd.
Inventors:
Thomas Zimmermann, Cristiana Boraschi, Knut Burgdorf, Catherine Caubere
Abstract: A storable biotransformation mixture that can oxidize a drug, comprising a cytochrome P450 enzyme, an electron donor; and, a buffer solution. In a preferred embodiment the mixture also contains liposomes, cytochrome b.sub.5 and NADPH-P450 reductase as the electron donor. The mixture is storable at a temperature less than 8.degree. C. to for at least two weeks and is able to oxidize a drug after storage.
Type:
Grant
Filed:
August 1, 1997
Date of Patent:
April 6, 1999
Assignee:
Panvera Corporation
Inventors:
Peter M. Shaw, Robert G. Lowery, David V. Thompson
Abstract: The invention provides a human lysophosphatidic acid acyltranferase (HLPAAT) and polynucleotides which identify and encode HLPAAT. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HLPAAT.
Type:
Grant
Filed:
February 25, 1998
Date of Patent:
March 30, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Henry Yue, Karl J. Guegler, Neil C. Corley
Abstract: Kex2 protease derivatives obtained by transforming methanol-assimilating with expression vectors containing DNA coding for any amino acid sequence which is an amino acid sequence of Kex2 protease wherein the N-terminus is the Met at position 1 and the C-terminus is one of the amino acids between positions 618 (inclusive) and 698 (inclusive), or a modification of that amino acid sequence, culturing the resulting transformants and recovering the derivatives from the cultures, as well as gene systems coding for the derivatives and a method for producing the Kex2 protease derivatives using the gene systems. Also, a method for excision of desired peptides using the Kex2 protease derivatives.
Type:
Grant
Filed:
March 4, 1997
Date of Patent:
March 23, 1999
Assignee:
Suntory Limited
Inventors:
Koji Magota, Toyofumi Masuda, Yuji Suzuki, Masayuki Yabuta
Abstract: The present invention relates to recombinant DNA which encodes the AgeI restriction endonuclease as well as AgeI methyltransferase, and production of AgeI restriction endonuclease from E. coli cells containing the recombinant DNA.
Type:
Grant
Filed:
May 14, 1998
Date of Patent:
March 23, 1999
Assignee:
New England Biolabs, Inc.
Inventors:
Shuang-yong Xu, Robert E. Maunus, Keith D. Lunnen, Rachel Allen
Abstract: A Thermococcus barosii DNA polymerase with reduced 3'-5' exonuclease activity is disclosed. Additionally disclosed is a Thermococcus barosii DNA polymerase with increased ability to incorporate ribonucleotides and dideoxynucleotides.
Type:
Grant
Filed:
August 4, 1997
Date of Patent:
March 16, 1999
Assignee:
Amersham Pharmacia Biotech Inc.
Inventors:
William A. Riedl, Susan J. Fly, Barbara F. Kaboord, Steven H. Nye, Eve Y. Ting
Abstract: An oxidized phospholipid degrading enzyme is provided, which plays an important role in the oxygen stress preventive mechanism in organisms. The enzyme hydrolyzes a 1-acyl-2-.omega.-carboxyfatty acid acyl-3-phosphatidylcholine as a substrate at the 2-ester bond thereof to form 1-acyl-2-lyso-3-phosphatidylcholine. The activity of the enzyme is slightly enhanced by 4 mM calcium chloride. The molecular mass of the enzyme is 95.+-.5 kDa (by gel filtration). The enzyme is composed of three subunits whose molecular masses have been found to be 29 kDa, 30 kDa and 45 kDa, respectively, by SDS-polyacrylamide electrophoresis. A gene coding the enzyme is also provided. This gene is important for the synthesis of the enzyme by genetic engineering.
Abstract: This invention relates to glutamine:fructose-6-phosphate amidotransferase, or its partial peptide or a salt thereof; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein; a pharmaceutical composition comprising the protein, its partial peptide or a salt thereof; and an antibody against the protein or its partial peptide. The protein, its partial peptide or a salt thereof, and the DNA are useful for a prophylactic or therapeutic agent for hypoglycemia. The antibody can be used in the assay of the protein, its partial peptide or a salt thereof. The protein, its partial peptide or a salt thereof is useful as a reagent for the screening for candidate medical compounds.
Abstract: Composition and methods for the expression of recombinant DNA polymerase enzymes derived from Bacillus stearothermophilus. The present invention also concerns methods for purifying recombinant Bst DNA polymerase enzymes, compositions containing the purified enzymes in a form suitable for conducting biochemical reactions, and methods for using the purified enzymes.
Type:
Grant
Filed:
May 8, 1995
Date of Patent:
February 23, 1999
Assignee:
Gen-Probe Incorporated
Inventors:
Michael Garth Riggs, Mathoor Sivaram, Starla Dianne Tudor
Abstract: The invention provides three human cell division regulators (HCDR) and polynucleotides which identify and encode HCDR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for preventing and treating disorders associated with expression of HCDR.
Type:
Grant
Filed:
October 15, 1997
Date of Patent:
February 16, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Olga Bandman, Preeti Lal, Purvi Shah, Neil C. Corley
Abstract: The invention provides a human mitochondrial processing peptidase subunit (MPPS-1) and polynucleotides which identify and encode MPPS-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of MPPS-1.
Type:
Grant
Filed:
July 17, 1997
Date of Patent:
February 9, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Purvi Shah, Neil C. Corley
Abstract: An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
February 9, 1999
Assignee:
Connaught Laboratories Limited
Inventors:
Sheena M. Loosmore, Yan-Ping Yang, Pele Chong, Raymond P. Oomen, Michel H. Klein
Abstract: Protein aggregates obtained by a process comprising culturing a host cell that expresses a desired protein in a medium comprising an effective amount of Cu.sup.++ and wherein the desired protein forms inclusion bodies in the host cell.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
February 2, 1999
Assignee:
Chiron Corporation
Inventors:
Lawrence S. Cousens, Patricia Tekamp-Olson
Abstract: The present invention relates to isolated polypeptides having phytase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. The present invention further relates to composite feeds and methods of reducing phytate levels.
Type:
Grant
Filed:
March 18, 1997
Date of Patent:
February 2, 1999
Assignee:
Novo Nordisk Biotech, Inc.
Inventors:
Randy M. Berka, Michael W. Rey, Alan V. Klotz
Abstract: This invention relates to nucleic acid and amino acid sequences of a new human ribonuclease and to the use of these sequences in the diagnosis, prevention and treatment of inflammation and disorders associated with cell proliferation and apoptosis.
Type:
Grant
Filed:
June 2, 1997
Date of Patent:
February 2, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Preeti Lal, Neil C. Corley
Abstract: A chimeric toxin comprising protein fragments joined together by peptide bonds, the chimeric toxin comprising, in sequential order, beginning at the amino terminal end of the chimeric toxin,(a) the enzymatically active Fragment A of diphtheria toxin,(b) a first fragment including the cleavage domain 1.sub.1 adjacent the Fragment A of diphtheria toxin,(c) a second fragment comprising at least a portion of the hydrophobic transmembrane region of Fragment B of diphtheria toxin, the second fragment having a deletion of at least 50 diphtheria toxin amino acid residues, the deletion being C-terminal to the portion of the transmembrane region, and the second fragment not including domain 1.sub.
Abstract: A nucleotide sequence encoding phytase has been isolated and cloned. The coding sequence has been inserted into an expression construct which in turn has been inserted into a vector capable of transforming a microbial expression host. The transformed microbial hosts may be used to economically produce phytase on an industrial scale. The phytase produced via the present invention may be used in a variety of processes requiring the conversion of phytate to inositol and inorganic phosphate.
Type:
Grant
Filed:
April 10, 1995
Date of Patent:
January 26, 1999
Assignee:
Gist-brocades, N.V.
Inventors:
Robert F.M. Van Gorcom, Willem Van Hartingsveldt, Petrus Andreas Van Paridon, Annemarie Eveline Veenstra, Rudolf G.M. Luiten, Gerardus C.M. Selten